{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T20:41:40Z","timestamp":1793306500511,"version":"4.5.0"},"reference-count":105,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,28]],"date-time":"2024-12-28T00:00:00Z","timestamp":1735344000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.biopha.2024.117805","type":"journal-article","created":{"date-parts":[[2025,1,4]],"date-time":"2025-01-04T20:55:31Z","timestamp":1736024131000},"page":"117805","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"special_numbering":"C","title":["Statins and non-alcoholic fatty liver disease: A concise review"],"prefix":"10.1016","volume":"183","author":[{"given":"Evelyn Nunes Goulart","family":"da Silva Pereira","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafaela Luiza Costa","family":"Franco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafaele Dantas Cruz dos","family":"Santos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anissa","family":"Daliry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopha.2024.117805_bib1","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1002\/ar.20715","article-title":"Hepatic microcirculation in fatty liver disease","volume":"291","author":"Farrell","year":"2008","journal-title":"Anat. Rec."},{"key":"10.1016\/j.biopha.2024.117805_bib2","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1002\/hep.23659","article-title":"Fatty liver: think globally","volume":"51","author":"Everhart","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.biopha.2024.117805_bib3","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1053\/gast.2002.34168","article-title":"Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma","volume":"123","author":"Bugianesi","year":"2002","journal-title":"Gastroenterology"},{"key":"10.1016\/j.biopha.2024.117805_bib4","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.cld.2004.04.004","article-title":"The clinical features, diagnosis and natural history of nonalcoholic fatty liver disease","volume":"8","author":"McCullough","year":"2004","journal-title":"Clin. Liver Dis."},{"key":"10.1016\/j.biopha.2024.117805_bib5","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/hep.28431","article-title":"Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence, and outcomes","volume":"64","author":"Younossi","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.biopha.2024.117805_bib6","doi-asserted-by":"crossref","first-page":"28705","DOI":"10.3390\/ijms161226126","article-title":"Current status of herbal medicines in chronic liver disease therapy: the biological effects, molecular targets and future prospects","volume":"16","author":"Hong","year":"2015","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.biopha.2024.117805_bib7","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/j.jhep.2017.05.016","article-title":"Treatment of NAFLD with diet, physical activity and exercise","volume":"67","author":"Romero-G\u00f3mez","year":"2017","journal-title":"J. Hepatol."},{"key":"10.1016\/j.biopha.2024.117805_bib8","article-title":"Proceedings: comparison of the effects of selective alpha and beta-receptor agonists on intracellular cyclic amp levels and glycogen phosphorylase activity in Guinea-Pig Liver","volume":"55","author":"Osborn","year":"1975","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.biopha.2024.117805_bib9","article-title":"Proceedings: Is ATP an inhibitory neurotransmitter in the rat stomach","volume":"55","author":"Heazell","year":"1975","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.biopha.2024.117805_bib10","doi-asserted-by":"crossref","first-page":"G407","DOI":"10.1152\/ajpgi.00441.2016","article-title":"Rationale for the use of statins in liver disease","volume":"312","author":"Schierwagen","year":"2017","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"10.1016\/j.biopha.2024.117805_bib11","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.jacc.2017.10.080","article-title":"Primary prevention with statins in the elderly","volume":"71","author":"Mortensen","year":"2018","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.biopha.2024.117805_bib12","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.1056\/NEJMoa1600176","article-title":"HOPE-3 Investigators, Cholesterol lowering in intermediate-risk persons without cardiovascular disease","volume":"374","author":"Yusuf","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.biopha.2024.117805_bib13","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.114.001709","article-title":"Trends in myocardial infarction secondary prevention: the National Health and Nutrition Examination Surveys (NHANES), 1999\u20132012","volume":"4","author":"Shah","year":"2015","journal-title":"J. Am. Heart Assoc."},{"key":"10.1016\/j.biopha.2024.117805_bib14","doi-asserted-by":"crossref","first-page":"3110","DOI":"10.2337\/dc20-1481","article-title":"Changes in statin use among U.S. adults with diabetes: a population-based analysis of NHANES 2011\u20132018","volume":"43","author":"Leino","year":"2020","journal-title":"Diabetes Care"},{"key":"10.1016\/j.biopha.2024.117805_bib15","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1016\/S0140-6736(11)61215-4","article-title":"Prospective Urban Rural Epidemiology (PURE) Study Investigators, Use of secondary prevention drugs for cardiovascular disease in the community in high-income, middle-income, and low-income countries (the PURE Study): a prospective epidemiological survey","volume":"378","author":"Yusuf","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.biopha.2024.117805_bib16","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1007\/s10620-015-4000-6","article-title":"Statins are underutilized in patients with nonalcoholic fatty liver disease and dyslipidemia","volume":"61","author":"Blais","year":"2016","journal-title":"Dig. Dis. Sci."},{"issue":"1","key":"10.1016\/j.biopha.2024.117805_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.jhep.2014.12.012","article-title":"NAFLD: a multisystem disease","volume":"62","author":"Byrne","year":"2015","journal-title":"J. Hepatol."},{"key":"10.1016\/j.biopha.2024.117805_bib18","doi-asserted-by":"crossref","first-page":"2296","DOI":"10.3390\/ijms21072296","article-title":"Targeting of secretory proteins as a therapeutic strategy for treatment of nonalcoholic steatohepatitis (NASH)","volume":"21","author":"Kim","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.biopha.2024.117805_bib19","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1055\/s-0032-1306423","article-title":"Dyslipidemia in patients with nonalcoholic fatty liver disease","volume":"32","author":"Chatrath","year":"2012","journal-title":"Semin. Liver Dis."},{"key":"10.1016\/j.biopha.2024.117805_bib20","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1007\/s11883-022-01028-4","article-title":"Management of dyslipidemia in patients with non-alcoholic fatty liver disease","volume":"24","author":"Martin","year":"2022","journal-title":"Curr. Atheroscler. Rep."},{"key":"10.1016\/j.biopha.2024.117805_bib21","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.livres.2022.05.002","article-title":"Non-alcoholic fatty liver disease development: a multifactorial pathogenic phenomena","volume":"6","author":"Bashir","year":"2022","journal-title":"Liver Res"},{"key":"10.1016\/j.biopha.2024.117805_bib22","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1136\/gut.2008.156307","article-title":"Toll-like receptors as targets in chronic liver diseases","volume":"58","author":"Mencin","year":"2009","journal-title":"Gut"},{"key":"10.1016\/j.biopha.2024.117805_bib23","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1053\/j.gastro.2019.12.054","article-title":"Adipose tissue-liver cross talk in the control of whole-body metabolism: Implications in nonalcoholic fatty liver disease","volume":"158","author":"Azzu","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1016\/j.biopha.2024.117805_bib24","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1038\/s41374-018-0120-x","article-title":"Activation of brown adipose tissue enhances the efficacy of caloric restriction for treatment of nonalcoholic steatohepatitis","volume":"99","author":"Poekes","year":"2019","journal-title":"Lab. Invest."},{"key":"10.1016\/j.biopha.2024.117805_bib25","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1136\/gutjnl-2019-319664","article-title":"Dietary cholesterol drives fatty liver-associated liver cancer by modulating gut microbiota and metabolites","volume":"70","author":"Zhang","year":"2021","journal-title":"Gut"},{"key":"10.1016\/j.biopha.2024.117805_bib26","doi-asserted-by":"crossref","first-page":"56","DOI":"10.3390\/biom12010056","article-title":"Understanding the role of the gut microbiome and microbial metabolites in non-alcoholic fatty liver disease: current evidence and perspectives","volume":"12","author":"Vallianou","year":"2021","journal-title":"Biomolecules"},{"key":"10.1016\/j.biopha.2024.117805_bib27","doi-asserted-by":"crossref","first-page":"20183","DOI":"10.1038\/s41598-019-56366-2","article-title":"Restoration of liver sinusoidal cell phenotypes by statins improves portal hypertension and histology in rats with NASH","volume":"9","author":"Bravo","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.biopha.2024.117805_bib28","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0032785","article-title":"Sinusoidal endothelial dysfunction precedes inflammation and fibrosis in a model of NAFLD","volume":"7","author":"Pasar\u00edn","year":"2012","journal-title":"PLOS ONE"},{"key":"10.1016\/j.biopha.2024.117805_bib29","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1002\/hep.20302","article-title":"Hepatic microvascular dysfunction during evolution of dietary steatohepatitis in mice","volume":"40","author":"McCuskey","year":"2004","journal-title":"Hepatology"},{"key":"10.1016\/j.biopha.2024.117805_bib30","doi-asserted-by":"crossref","first-page":"5034","DOI":"10.3390\/nu15245034","article-title":"Cholesterol exacerbates the pathophysiology of non-alcoholic steatohepatitis by upregulating hypoxia-inducible factor 1 and modulating microcirculatory dysfunction","volume":"15","author":"E.N.G.D.S. Pereira","year":"2023","journal-title":"Nutrients"},{"key":"10.1016\/j.biopha.2024.117805_bib31","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1038\/cr.2008.61","article-title":"Feedback regulation of cholesterol synthesis: Sterol-accelerated ubiquitination and degradation of HMG CoA reductase","volume":"18","author":"DeBose-Boyd","year":"2008","journal-title":"Cell Res"},{"key":"10.1016\/j.biopha.2024.117805_bib32","doi-asserted-by":"crossref","first-page":"484","DOI":"10.2183\/pjab.86.484","article-title":"A historical perspective on the discovery of statins","volume":"86","author":"Endo","year":"2010","journal-title":"Proc. Jpn Acad. Ser. B Phys. Biol. Sci."},{"key":"10.1016\/j.biopha.2024.117805_bib33","doi-asserted-by":"crossref","first-page":"419","DOI":"10.3109\/07853890.2011.582135","article-title":"Clinical response to statins: Mechanism(s) of variable activity and adverse effects","volume":"44","author":"Sirtori","year":"2012","journal-title":"Ann. Med."},{"key":"10.1016\/j.biopha.2024.117805_bib34","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.phrs.2014.03.002","article-title":"The pharmacology of statins","volume":"88","author":"Sirtori","year":"2014","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.biopha.2024.117805_bib35","doi-asserted-by":"crossref","first-page":"231","DOI":"10.3949\/ccjm.87a.19078","article-title":"lipid guidelines, ACC\/AHA lipid guidelines: personalized care to prevent cardiovascular disease","volume":"87","author":"Reiter-Brennan","year":"2020","journal-title":"Cleve. Clin. J. Med."},{"key":"10.1016\/j.biopha.2024.117805_bib36","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1136\/bmj.326.7404.1423","article-title":"Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: Systematic review and meta-analysis","volume":"326","author":"Law","year":"2003","journal-title":"BMJ"},{"key":"10.1016\/j.biopha.2024.117805_bib37","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1111\/jgh.12212","article-title":"Non-alcoholic steatohepatitis: Pathogenesis and novel therapeutic approaches","volume":"28 1","author":"Schuppan","year":"2013","journal-title":"J. Gastroenterol. Hepatol."},{"key":"10.1016\/j.biopha.2024.117805_bib38","doi-asserted-by":"crossref","first-page":"202","DOI":"10.3389\/fmed.2019.00202","article-title":"Cardiovascular risk in fatty liver disease: The liver-heart axis-literature review","volume":"6","author":"Ismaiel","year":"2019","journal-title":"Front. Med. (Lausanne)."},{"key":"10.1016\/j.biopha.2024.117805_bib39","doi-asserted-by":"crossref","first-page":"351","DOI":"10.5551\/jat.7591","article-title":"Inflammation and the development of atherosclerosis","volume":"18","author":"Mizuno","year":"2011","journal-title":"J. Atheroscler. Thromb."},{"key":"10.1016\/j.biopha.2024.117805_bib40","doi-asserted-by":"crossref","first-page":"23","DOI":"10.14797\/mdcj-15-1-23","article-title":"Statins: then and now","volume":"15","author":"Toth","year":"2019","journal-title":"Methodist Debakey CardioVasc J."},{"key":"10.1016\/j.biopha.2024.117805_bib41","doi-asserted-by":"crossref","first-page":"78","DOI":"10.14218\/JCTH.2014.00037","article-title":"Nonalcoholic fatty liver disease: Dyslipidemia, risk for cardiovascular complications, and treatment strategy","volume":"3","author":"Zhang","year":"2015","journal-title":"J. Clin. Transl. Hepatol."},{"key":"10.1016\/j.biopha.2024.117805_bib42","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/j.medcli.2017.11.030","article-title":"Statins: Pros and cons","volume":"150","author":"Pinal-Fernandez","year":"2018","journal-title":"Med. Clin."},{"key":"10.1016\/j.biopha.2024.117805_bib43","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2022.104392","article-title":"Dissecting the multifaceted impact of statin use on fatty liver disease: a multidimensional study","volume":"87","author":"Ayada","year":"2023","journal-title":"EBiomedicine"},{"key":"10.1016\/j.biopha.2024.117805_bib44","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1161\/CIRCULATIONAHA.108.813311","article-title":"Evidence for statin pleiotropy in humans: Differential effects of statins and ezetimibe on rho-associated coiled-coil containing protein kinase activity, endothelial function, and inflammation","volume":"119","author":"Liu","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.biopha.2024.117805_bib45","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1080\/14740338.2020.1796966","article-title":"Statin use and safety concerns: An overview of the past, present, and the future","volume":"19","author":"Mulchandani","year":"2020","journal-title":"Expert Opin. Drug Saf."},{"key":"10.1016\/j.biopha.2024.117805_bib46","doi-asserted-by":"crossref","DOI":"10.1177\/1179552218787502","article-title":"An evidence-based review of statin use in patients with nonalcoholic fatty liver disease","volume":"11","author":"Sigler","year":"2018","journal-title":"Clin. Med. Insights Gastroenterol."},{"issue":"6","key":"10.1016\/j.biopha.2024.117805_bib47","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1007\/s10620-015-4000-6","article-title":"Statins: Underutilization in patients with nonalcoholic fatty liver disease and dyslipidemia","volume":"61","author":"Blais","year":"2016","journal-title":"Dig. Dis. Sci."},{"issue":"1","key":"10.1016\/j.biopha.2024.117805_bib48","doi-asserted-by":"crossref","first-page":"e17","DOI":"10.1097\/MJT.0000000000001499","article-title":"Statins for the treatment of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: a systematic review and meta-analysis","volume":"30","author":"Dai","year":"2023","journal-title":"Am. J. Ther."},{"key":"10.1016\/j.biopha.2024.117805_bib49","doi-asserted-by":"crossref","first-page":"9326","DOI":"10.3390\/ijms23169326","article-title":"Statins in high cardiovascular risk patients: do comorbidities and characteristics matter?","volume":"23","author":"Rossini","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.biopha.2024.117805_bib50","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1177\/1074248415578170","article-title":"Statins and nonadherence: should we RELATE better?","volume":"20","author":"Turin","year":"2015","journal-title":"J. Cardiovasc. Pharmacol. Ther."},{"key":"10.1016\/j.biopha.2024.117805_bib51","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1253\/circj.CJ-10-0110","article-title":"Pleiotropic effects of statins. \u2013 Basic research and clinical perspectives","volume":"74","author":"Zhou","year":"2010","journal-title":"Circ. J."},{"key":"10.1016\/j.biopha.2024.117805_bib52","doi-asserted-by":"crossref","first-page":"716","DOI":"10.3390\/nu14030716","article-title":"Simvastatin improves microcirculatory function in nonalcoholic fatty liver disease and downregulates oxidative and ALE-RAGE stress","volume":"14","author":"E.N.G.D.S. Pereira","year":"2022","journal-title":"Nutrients"},{"key":"10.1016\/j.biopha.2024.117805_bib53","doi-asserted-by":"crossref","first-page":"3201873","DOI":"10.1155\/2019\/3201873","article-title":"Simvastatin reduces hepatic oxidative stress and endoplasmic reticulum stress in nonalcoholic steatohepatitis experimental model","volume":"2019","author":"Rodrigues","year":"2019","journal-title":"Oxid. Med. Cell. Longev."},{"key":"10.1016\/j.biopha.2024.117805_bib54","doi-asserted-by":"crossref","first-page":"7818","DOI":"10.3390\/ijms24097818","article-title":"Atorvastatin attenuates diet-induced non-alcoholic steatohepatitis in APOE*3-Leiden mice by reducing hepatic inflammation","volume":"24","author":"Inia","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.biopha.2024.117805_bib55","article-title":"Simvastatin ameliorates liver fibrosis via mediating nitric oxide synthase in rats with non-alcoholic steatohepatitis-related liver fibrosis","volume":"8","author":"Wang","year":"2013","journal-title":"PLOS ONE"},{"key":"10.1016\/j.biopha.2024.117805_bib56","article-title":"Pleiotropic effects of statins in the light of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis","volume":"12","author":"Ahsan","year":"2020","journal-title":"Cureus"},{"key":"10.1016\/j.biopha.2024.117805_bib57","doi-asserted-by":"crossref","first-page":"G724","DOI":"10.1152\/ajpgi.00063.2016","article-title":"Statins improve NASH via inhibition of RhoA and Ras","volume":"311","author":"Schierwagen","year":"2016","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"10.1016\/j.biopha.2024.117805_bib58","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.ajg.2011.04.008","article-title":"Paraoxonase-1 activity, malondialdehyde and glutathione peroxidase in non-alcoholic fatty liver disease and the effect of atorvastatin","volume":"12","author":"Samy","year":"2011","journal-title":"Arab J. Gastroenterol."},{"key":"10.1016\/j.biopha.2024.117805_bib59","doi-asserted-by":"crossref","first-page":"376","DOI":"10.4093\/dmj.2016.40.5.376","article-title":"Statins increase mitochondrial and peroxisomal fatty acid oxidation in the liver and prevent non-alcoholic steatohepatitis in mice","volume":"40","author":"Park","year":"2016","journal-title":"Diabetes Metab. J."},{"key":"10.1016\/j.biopha.2024.117805_bib60","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1194\/jlr.M053785","article-title":"Cholesterol-lowering drugs cause dissolution of cholesterol crystals and disperse Kupffer cell crown-like structures during resolution of NASH","volume":"56","author":"Ioannou","year":"2015","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.biopha.2024.117805_bib61","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1002\/hep.26127","article-title":"Effects of simvastatin administration on rodents with lipopolysaccharide-induced liver microvascular dysfunction","volume":"57","author":"La Mura","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.biopha.2024.117805_bib62","doi-asserted-by":"crossref","first-page":"4913","DOI":"10.3748\/wjg.v27.i29.4913","article-title":"Advanced glycation end product: a potential biomarker for risk stratification of non-alcoholic fatty liver disease in ELSA-Brasil study","volume":"27","author":"E.N.G.D.S. Pereira","year":"2021","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.biopha.2024.117805_bib63","article-title":"Hepatic microvascular dysfunction and increased advanced glycation end products are components of non-alcoholic fatty liver disease","volume":"12","author":"E.N.G.D.S. Pereira","year":"2017","journal-title":"PLOS ONE"},{"key":"10.1016\/j.biopha.2024.117805_bib64","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1161\/01.ATV.0000043456.48735.20","article-title":"HMG-CoA Reductase Inhibitors regulate inflammatory transcription factors in human endothelial and vascular smooth muscle cells","volume":"23","author":"Dichtl","year":"2003","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.biopha.2024.117805_bib65","doi-asserted-by":"crossref","first-page":"4935","DOI":"10.1007\/s12035-023-03371-2","article-title":"The effect of simvastatin on the dynamics of NF-\u03baB-regulated neurodegenerative and neuroprotective processes in the acute phase of ischemic stroke","volume":"60","author":"Lietzau","year":"2023","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.biopha.2024.117805_bib66","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1007\/s12640-017-9784-z","article-title":"RAGE-NF-\u03baB-PPAR\u03b3 signaling is involved in AGEs-induced upregulation of amyloid-\u03b2 influx transport in an in vitro BBB model","volume":"33","author":"Chen","year":"2018","journal-title":"Neurotox. Res."},{"key":"10.1016\/j.biopha.2024.117805_bib67","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1007\/s10753-017-0516-6","article-title":"Simvastatin inhibits IL-1\u03b2-induced apoptosis and extracellular matrix degradation by suppressing the NF-kB and MAPK pathways in nucleus pulposus cells","volume":"40","author":"Tu","year":"2017","journal-title":"Inflammation"},{"key":"10.1016\/j.biopha.2024.117805_bib68","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1161\/CIRCULATIONAHA.112.095554","article-title":"Immediate antioxidant and antiplatelet effect of atorvastatin via inhibition of Nox2","volume":"126","author":"Pignatelli","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.biopha.2024.117805_bib69","doi-asserted-by":"crossref","first-page":"24266","DOI":"10.1074\/jbc.273.37.24266","article-title":"Post-transcriptional regulation of endothelial nitric oxide synthase mRNA stability by Rho GTPase","volume":"273","author":"Laufs","year":"1998","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.biopha.2024.117805_bib70","doi-asserted-by":"crossref","first-page":"2442","DOI":"10.1161\/01.STR.31.10.2442","article-title":"Atorvastatin upregulates type III nitric oxide synthase in thrombocytes, decreases platelet activation, and protects from cerebral ischemia in normocholesterolemic mice","volume":"31","author":"Laufs","year":"2000","journal-title":"Stroke"},{"key":"10.1016\/j.biopha.2024.117805_bib71","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.1111\/j.1523-1755.2000.00340.x","article-title":"Nitric oxide inhibits the formation of advanced glycation end products","volume":"58","author":"Asahi","year":"2000","journal-title":"Kidney Int"},{"key":"10.1016\/j.biopha.2024.117805_bib72","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1038\/s41569-018-0098-5","article-title":"Safety and efficacy of statin therapy","volume":"15","author":"Adhyaru","year":"2018","journal-title":"Nat. Rev. Cardiol."},{"key":"10.1016\/j.biopha.2024.117805_bib73","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1111\/bcp.14943","article-title":"Statin liver safety in non-alcoholic fatty liver disease: a systematic review and metanalysis","volume":"88","author":"Pastori","year":"2022","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"7","key":"10.1016\/j.biopha.2024.117805_bib74","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1007\/s11926-024-01143-y","article-title":"Decoding the intricacies of statin-associated muscle symptoms","volume":"26","author":"Rastegar","year":"2024","journal-title":"Curr. Rheuma Rep."},{"issue":"5","key":"10.1016\/j.biopha.2024.117805_bib75","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1002\/phar.2681","article-title":"Statin-associated muscle symptoms-A review: Individualizing the approach to optimize care","volume":"42","author":"Wiggins","year":"2022","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.biopha.2024.117805_bib76","article-title":"Recurrence of statin-induced necrotizing myopathy: a learning point","volume":"16","author":"Toorani","year":"2024","journal-title":"Cureus"},{"key":"10.1016\/j.biopha.2024.117805_bib77","doi-asserted-by":"crossref","first-page":"8364","DOI":"10.3390\/ijms23158364","article-title":"Statins neuromuscular adverse effects","volume":"23","author":"Attardo","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.biopha.2024.117805_bib78","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.jacl.2022.09.001","article-title":"Assessment and management of statin-associated muscle symptoms (SAMS): a clinical perspective from the National Lipid Association","volume":"17","author":"Warden","year":"2023","journal-title":"J. Clin. Lipido"},{"key":"10.1016\/j.biopha.2024.117805_bib79","first-page":"721","article-title":"Treatment with statins in elderly patients","volume":"55","author":"Horodinschi","year":"2019","journal-title":"Med. (Kaunas. )"},{"key":"10.1016\/j.biopha.2024.117805_bib80","doi-asserted-by":"crossref","first-page":"75","DOI":"10.3390\/jcm6080075","article-title":"Statins, muscle disease and mitochondria","volume":"6","author":"Ramachandran","year":"2017","journal-title":"J. Clin. Med."},{"issue":"3","key":"10.1016\/j.biopha.2024.117805_bib81","article-title":"Statin-associated myopathy: From genetic predisposition to clinical management","volume":"63","author":"Vrablik","year":"2014","journal-title":"Physiol. Res."},{"key":"10.1016\/j.biopha.2024.117805_bib82","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1111\/eci.12461","article-title":"The role of mitochondria in statin-induced myopathy","volume":"45","author":"Apostolopoulou","year":"2015","journal-title":"Eur. J. Clin. Investig."},{"key":"10.1016\/j.biopha.2024.117805_bib83","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.2522\/ptj.20090251","article-title":"Effects of statins on skeletal muscle: a perspective for physical therapists","volume":"90","author":"Di Stasi","year":"2010","journal-title":"Phys. Ther."},{"issue":"4","key":"10.1016\/j.biopha.2024.117805_bib84","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1016\/S1734-1140(11)70601-6","article-title":"Statin-induced myopathies","volume":"63","author":"Tomaszewski","year":"2011","journal-title":"Pharm. Rep."},{"key":"10.1016\/j.biopha.2024.117805_bib85","unstructured":"Shrestha A., Mulmi A., Munankarmi R. Statins and Abnormal Liver Enzymes. S D Med. 2019;72(1):12-14. https:\/\/doi.org\/10.1016\/j.jacl.2022.09.001. (Epub 2019 January 12). \u3008http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/30849222\u3009."},{"key":"10.1016\/j.biopha.2024.117805_bib86","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.3390\/molecules29081859","article-title":"A systematic review of statins for the treatment of nonalcoholic steatohepatitis: safety, efficacy, and mechanism of action","volume":"29","author":"Zhang","year":"2024","journal-title":"Molecules"},{"key":"10.1016\/j.biopha.2024.117805_bib87","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2021.777131","article-title":"Statins in non-alcoholic steatohepatitis","volume":"8","author":"Torres-Pe\u00f1a","year":"2021","journal-title":"Front. Cardiovasc. Med."},{"key":"10.1016\/j.biopha.2024.117805_bib88","doi-asserted-by":"crossref","first-page":"5232","DOI":"10.1097\/MS9.0000000000001231","article-title":"Low-dose atorvastatin therapy induced rhabdomyolysis in a liver cirrhosis patient - a case report","volume":"85","author":"Bhattarai","year":"2023","journal-title":"Ann. Med. Surg. (Lond. )"},{"issue":"7","key":"10.1016\/j.biopha.2024.117805_bib89","first-page":"449","article-title":"Statins and elevated liver tests: what's the fuss?","volume":"57","author":"Onusko","year":"2008","journal-title":"J. Fam. Pr."},{"issue":"12","key":"10.1016\/j.biopha.2024.117805_bib90","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1016\/j.jacc.2021.07.022","article-title":"Side effect patterns in a crossover trial of statin, placebo, and no treatment","volume":"78","author":"Howard","year":"2021","journal-title":"J. Am. Coll. Cardiol."},{"issue":"2","key":"10.1016\/j.biopha.2024.117805_bib91","doi-asserted-by":"crossref","first-page":"e38","DOI":"10.1161\/ATV.0000000000000073","article-title":"American Heart Association clinical lipidology, lipoprotein, metabolism and thrombosis committee. statin safety and associated adverse events: a scientific statement from the American Heart Association","volume":"39","author":"Newman","year":"2019","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"6","key":"10.1016\/j.biopha.2024.117805_bib92","first-page":"711","article-title":"Norrell A. Considerations for safe use of statins: liver enzyme abnormalities and muscle toxicity","volume":"83","author":"Gillett","year":"2011","journal-title":"Am. Fam. Physician"},{"issue":"4","key":"10.1016\/j.biopha.2024.117805_bib93","doi-asserted-by":"crossref","first-page":"349","DOI":"10.4065\/mcp.2009.0365","article-title":"Statins in the treatment of dyslipidemia in the presence of elevated liver aminotransferase levels: a therapeutic dilemma","volume":"85","author":"Calderon","year":"2010","journal-title":"Mayo Clin. Proc."},{"issue":"1","key":"10.1016\/j.biopha.2024.117805_bib94","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.jhep.2007.02.013","article-title":"Statins in non-alcoholic fatty liver disease and chronically elevated liver enzymes: a histopathological follow-up study","volume":"47","author":"Ekstedt","year":"2007","journal-title":"J. Hepatol."},{"key":"10.1016\/j.biopha.2024.117805_bib95","doi-asserted-by":"crossref","first-page":"645","DOI":"10.5114\/aoms.2016.59938","article-title":"Molecular mechanisms of statin intolerance","volume":"12","author":"Gluba-Brzozka","year":"2016","journal-title":"Arch. Med. Sci."},{"key":"10.1016\/j.biopha.2024.117805_bib96","first-page":"80","article-title":"Statins and liver","volume":"161","author":"Hlu\u0161i\u010dka","year":"2022","journal-title":"Cas. Lek. Cesk."},{"issue":"2","key":"10.1016\/j.biopha.2024.117805_bib97","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1097\/MCG.0000000000001503","article-title":"Effect of statin use on cancer-related mortality in nonalcoholic fatty liver disease: a prospective united states cohort study","volume":"56","author":"Hajifathalian","year":"2022","journal-title":"J. Clin. Gastroenterol."},{"issue":"9756","key":"10.1016\/j.biopha.2024.117805_bib98","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1016\/S0140-6736(10)61272-X","volume":"376","author":"Athyros","year":"2010","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.biopha.2024.117805_bib99","doi-asserted-by":"crossref","first-page":"116","DOI":"10.14309\/ajg.0000000000000845","article-title":"Effects of statin use on the development and progression of nonalcoholic fatty liver disease: a nationwide nested case-control study","volume":"116","author":"Lee","year":"2021","journal-title":"Am. J. Gastroenterol."},{"issue":"3","key":"10.1016\/j.biopha.2024.117805_bib100","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/j.jhep.2015.05.006","article-title":"Statin use and non-alcoholic steatohepatitis in at-risk individuals","volume":"63","author":"Dongiovanni","year":"2015","journal-title":"J. Hepatol."},{"issue":"5","key":"10.1016\/j.biopha.2024.117805_bib101","doi-asserted-by":"crossref","first-page":"572","DOI":"10.2174\/1570161118666201015152921","article-title":"Prevalence, Diagnosis, and Treatment with 3 different statins of non-alcoholic fatty liver disease\/non-alcoholic steatohepatitis in military personnel: do genetics play a role?","volume":"19","author":"Sfikas","year":"2021","journal-title":"Curr. Vasc. Pharm."},{"issue":"8","key":"10.1016\/j.biopha.2024.117805_bib102","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1097\/MCG.0000000000001260","article-title":"Statin use is protective against hepatocellular carcinoma in patients with nonalcoholic fatty liver disease: a case-control study","volume":"54","author":"German","year":"2020","journal-title":"J. Clin. Gastroenterol."},{"issue":"1","key":"10.1016\/j.biopha.2024.117805_bib103","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.atherosclerosis.2004.01.008","article-title":"Pravastatin in patients with nonalcoholic steatohepatitis: results of a pilot study","volume":"174","author":"Rallidis","year":"2004","journal-title":"Atherosclerosis"},{"issue":"10","key":"10.1016\/j.biopha.2024.117805_bib104","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1097\/MCG.0b013e31819c392e","article-title":"A pilot study using simvastatin in the treatment of nonalcoholic steatohepatitis: a randomized placebo-controlled trial","volume":"43","author":"Nelson","year":"2009","journal-title":"J. Clin. Gastroenterol."},{"issue":"11","key":"10.1016\/j.biopha.2024.117805_bib105","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1111\/j.1872-034X.2011.00849.x","article-title":"Efficacy of pitavastatin for the treatment of non-alcoholic steatohepatitis with dyslipidemia: an open-label pilot study","volume":"41","author":"Hyogo","year":"2011","journal-title":"Hepatol. Res"}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332224016925?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332224016925?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,8]],"date-time":"2025-05-08T21:50:45Z","timestamp":1746741045000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332224016925"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":105,"alternative-id":["S0753332224016925"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2024.117805","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Statins and non-alcoholic fatty liver disease: A concise review","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2024.117805","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"117805"}}